The Deal Register
Database › M&A › DRI Healthcare Trust Announces Acquisition of a Synthetic Royalty…

M&A

DRI Healthcare Trust Announces Acquisition of a Synthetic Royalty Interest in the U.S. Sales of Veligrotug…

Lane
M&A
Announced
20 Oct 2025
Province
Ontario
Industry
Healthcare & life sciences
Status
Announced
What the filing says
DRI Healthcare Trust (TSX: DHT.UN ) (TSX: DHT.U ) ("DRI Healthcare"), a global leader in providing financing to advance innovation in the life sciences industry, has acquired a royalty interest in the U.S. net sales of veligrotug (formerly known as VRDN-001) and VRDN-003 from Viridian Therapeutics, Inc. (Nasdaq: VRDN) for an aggregate purchase price of up to US$300 million, including a US$55 million upfront payment and up to US$115 million in near-term clinical and regulatory milestone payments.
Source

The terms are in the subscriber edition

This transaction carries the consideration.

Subscribe

Compiled from public filings, court documents, exchange bulletins and issuer releases. Figures are as disclosed and are not independently verified.

Not financial, investment, legal or tax advice, and not an offer to buy or sell any security. Verify everything before you transact.

The Deal Register · Archive · Subscribe